Sluggish Copaxone Rival And Delay To Generic Advair Hurt Mylan

 
• By Dave Wallace

Mylan has blamed a sluggish uptake for its Copaxone rival and a delay in FDA approval of its generic version of Advair Diskus for the firm’s sales suffering a 4% drop and EBITDA falling by 8% in 2018.

Snail
Slower Than Expected Uptake For Glatiramer And A Delay To Wixela Inhub’s Approval Hit Mylan In 2018 • Source: Shutterstock

More from Earnings

More from Business